Search

Displaying results 3731 - 3740 of 8974 in total
  1. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  2. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

  3. Drug

    Vanadium

    go.drugbank.com/drugs/DB13971
    Approved

    Mixtures: Doctor's Choice Brand for Men, Multivitamins and Minerals for Men
  4. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

    Mixtures: CERNEVIT FOR INJECTION, Cernevit, Lyophilisate for Reconstitution
  5. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use.

  6. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S. … FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  7. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476]. … Proxibarbal is a derivative of barbiturates, which has been used to treat migraines.

  8. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific … T-cell engager to receive marketing approval.

  9. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

  10. Drug

    Litifilimab

    go.drugbank.com/drugs/DB18864
    Investigational

    SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy). … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (